Top

Cancer Chemotherapy and Pharmacology

Published in:

01-04-2013 | Original Article

Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term

Authors: Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2013

Abstract

Purpose

To study the correlation between expression levels of ERCC1/TS mRNA and the susceptibility of preoperative chemotherapy for patients with gastric cancer.

Methods

A total of forty cases with advanced gastric cancer of T3–4N1–2M0 were treated with preoperative chemotherapy according to FLEEOX regimen based on endarterial-intravenous coadministration. Sufficient, fresh gastric tissue specimens were obtained with the help of gastroscope, and the expression levels of ERCC1/TS mRNA were detected by qRT-PCR before chemotherapy. The chemotherapeutic response was evaluated with Choi Criteria after chemotherapy, and pathologic remission extent was observed after surgery. The correlation between the expression levels of ERCC1/TS mRNA before chemotherapy and the chemotherapeutic effect based on imageology and pathology was analyzed.

Results

The response rate of Chemotherapy in this cohort was 80.0 % based on imageology and 51.43 % based on pathology. The expression levels of ERCC1/TS mRNA were significantly associated with imageology remission extent (P = 0.033, P = 0.025) and pathologic remission extent (P = 0.044, P = 0.016), respectively. The chemotherapeutic effect on patients with low-expression levels of ERCC1/TS mRNA was better.

Conclusions

From the perspective of pathology and imageology evaluating the preoperative chemotherapeutic response for patients with gastric cancer, ERCC1 and TS were used as the molecular predictors and provided prognostic information in this study.

Yang L (2006) Incidence and mortality of gastric cancer in China. World J Gastroenterol 12(1):17–20PubMed

Chua YJ, Cunningham D (2007) The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice. Ann Surg Oncol 14(10):2687–2690. doi:10.1245/s10434-007-9423-7 PubMedCrossRef

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20. doi:10.1056/NEJMoa055531 PubMedCrossRef

Li G-L, Bao Y, Jiang J, Fan C-G, Wang Z-M, Li N, Li J-S (2008) Arteriovenous neoadjuvant FLEOX chemotherapy with nutritional support improves the resectable rate for advanced gastric cancer. Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery (5)

Li GL, Fan CG, Bao Y, Jiang J, Li N, Li JS (2009) Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases. Zhonghua Wai Ke Za Zhi 47(15):1171–1174PubMed

Hwang SW, Lee DH, Lee SH, Park YS, Hwang JH, Kim JW, Jung SH, Kim NY, Kim YH, Lee KH, Kim HH, J Park do, HS Lee, HC Jung, IS Song (2010) Preoperative staging of gastric cancer by endoscopic ultrasonography and multidetector-row computed tomography. J Gastroenterol Hepatol 25(3):512–518. doi:10.1111/j.1440-1746.2009.06106.x PubMedCrossRef

Association JGC (2010) Japanese classification of gastric carcinoma, 14th ed (in Japanese). Kanehara & Co, Ltd., Tokyo

Liu K, Li G, Fan C, Zhou C, Li J (2012) Adapted choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 53(2):127–134. doi:10.1258/ar.2011.110273 PubMedCrossRef

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25(4):402–408. doi:10.1006/meth.2001.1262 PubMedCrossRef

10.

Hofler H, Langer R, Ott K, Keller G (2007) Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Recent Results Cancer Res 176:33–36PubMedCrossRef

11.

Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16(1):309–316PubMed

12.

Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ, Zhao Y, Feng J, Ling Y, Liu Y, Yu L, Rosell R, Liu B (2008) ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Brit J Cancer 98(8):1398–1402. doi:10.1038/sj.bjc.6604317 PubMedCrossRef

13.

Yeh CN, Jung SM, Chen TW, Hwang TL, Jan YY, Chen MF (2010) Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbecks Arch Surg 395(3):217–225. doi:10.1007/s00423-009-0573-x PubMedCrossRef

14.

Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M (2006) Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 24(3):235–241. doi:10.1080/07357900600632082 PubMedCrossRef

15.

Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18(3):504–509. doi:10.1093/annonc/mdl430 PubMedCrossRef

16.

Yun J, Kim KM, Kim ST, Kim JH, Kim JA, Kong JH, Lee SH, Won YW, Sun JM, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK (2010) Predictive value of the ERCC1 expression for treatment response and survival in advanced gastric cancer patients receiving cisplatin-based first-line chemotherapy. Cancer Res Treat 42(2):101–106. doi:10.4143/crt.2010.42.2.101 PubMedCrossRef

17.

Klein D (2002) Quantification using real-time PCR technology: applications and limitations. Trends Mol Med 8(6):257–260PubMedCrossRef

18.

Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K (2008) Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer. Br J Cancer 98(4):832–839. doi:10.1038/sj.bjc.6604211 PubMedCrossRef

19.

Zhang C, Li G, Fan C, Xu J, Cao J, Liu S, Li N (2012) Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World J Surg Oncol 10(1):162. doi:10.1186/1477-7819-10-162 PubMedCrossRef

20.

Sonnenblick A, Rottenberg Y, Kadouri L, Wygoda M, Rivkind A, Vainer GW, Peretz T, Hubert A (2012) Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. Med Oncol 29(5):3035–3038. doi:10.1007/s12032-012-0302-0 PubMedCrossRef

21.

Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55(7):1407–1412PubMed

22.

Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98(7):1521–1530. doi:10.1002/cncr.11660 PubMedCrossRef

23.

Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, Friess H, Hofler H (2011) Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 253(5):934–939. doi:10.1097/SLA PubMedCrossRef

Title: Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
Authors: Liqi Chen
Guoli Li
Jieshou Li
Chaogang Fan
Jian Xu
Bo Wu
Kun Liu
Caihua Zhang
Publication date: 01-04-2013
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2083-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Erratum to: Pharmacokinetic–pharmacodynamic relationship of bosutinib in patients with chronic-phase chronic myeloid leukemia

A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas

The PPARγ agonist pioglitazone crosses the blood–brain barrier and reduces tumor growth in a human xenograft model

Multicenter phase II trial of preoperative chemoradiotherapy with S-1 for locally advanced oral squamous cell carcinoma

Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer